LUPIN.NS · Intrinsic value
Is Lupin Limited (LUPIN.NS) overvalued or undervalued?
Lupin Limited (LUPIN.NS) trades at the delayed market price of ₹1,965.20 a share. That price already implies revenue growth of 2.7% a year for 5 years. TickerWorth's fair value is ₹3,004.46 a share (priced within our range of ₹878.93 – ₹3,546.15). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
Is LUPIN.NS fairly valued?
- Fair value
- ₹3,004.46
- Market price
- ₹1,965.20
- Upside to fair value
- +52.9%
- Verdict
- Priced within our range of ₹878.93 – ₹3,546.15
Reverse DCF: Today's price implies revenue growth of 2.7% a year for 5 years; our model assumes 16.6% a year on average over the same horizon.
What is LUPIN.NS's TickerWorth Score?
Scores higher than almost every company we compare it with
Compared with Healthcare companies in India
Its strongest point: looks cheap on the numbers. Its weakest: recent price trend has been weak.
- Value · 93 of 100
Cheaper than 93% of Healthcare companies in India
- Price vs worth · 92 of 100
- Quality · 84 of 100
More profitable than 84% of Healthcare companies in India
- Financial health · 58 of 100
Financially stronger than 58% of Healthcare companies in India
- Growth · 44 of 100
Growing faster than 44% of Healthcare companies in India
- Momentum · 21 of 100
Outperformed 21% of Healthcare companies in India over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
LUPIN.NS DCF valuation, input by input
TickerWorth's fair value for Lupin Limited (LUPIN.NS) is ₹3,004.46 a share, against the delayed market price of ₹1,965.20 (priced within our range of ₹878.93 – ₹3,546.15). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below. This is an educational model, not a price target or a recommendation.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values LUPIN.NS at about ₹3,546 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts Lupin Limited's projected free cash flows at a weighted-average cost of capital (WACC) of 9.5%, with a long-run terminal growth rate of 2.5%. About 75% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 2.7% annual revenue growth for LUPIN.NS. Our base case instead compounds to about 16.6% a year over the same forecast, so the market is pricing in slower growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, LUPIN.NS's modeled DCF value ranges from about ₹2,674 to ₹5,377 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Lupin Limited would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of LUPIN.NS's intrinsic value. Figures update as new filings and prices come in.
Every input behind LUPIN.NS's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | ₹299,665,780,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 25.4% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 30% → 24% → 17% → 10% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.1% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.00 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 457M |
| Market priceLast known price · as of 2026-10-19 13:20 UTC | ₹1,965 |
Change LUPIN.NS's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Lupin Limited do?
What does it do?
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector), headquartered in India. The company employs roughly 26,021 people.
How does it make money?
The business turns 299.7B in annual revenue into profit. Out of every $100 of sales, about $25 is left as operating profit (operating margin of 25.4%), after a 72% gross margin on the products/services it sells. After all costs, taxes and interest, 18.5% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.3× equity), and is currently profitable.
LUPIN.NS insider trading
Insider filings are available for US-listed companies only.
Common questions
What is LUPIN.NS's intrinsic value?
TickerWorth's blended fair value for Lupin Limited (LUPIN.NS) is ₹3,004.46 per share, versus a market price of ₹1,965.20 (priced within our range of ₹878.93 – ₹3,546.15).
Is LUPIN.NS overvalued or undervalued?
Priced within our range of ₹878.93 – ₹3,546.15 at ₹1,965.20. We don't call LUPIN.NS overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for LUPIN.NS?
A WACC of 9.5% and a terminal growth rate of 2.5%.
Is Lupin stock undervalued?
TickerWorth's fair value for Lupin Limited (LUPIN.NS) is ₹3,004.46 against a market price of ₹1,965.20. Our read: Priced within our range of ₹878.93 – ₹3,546.15. This is a model estimate, not investment advice.
Lupin (LUPIN.NS) DCF valuation and fair value
Our fair value for Lupin Limited (LUPIN.NS) is ₹3,004.46, built on a 9.5% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Lupin stock?
Today's price implies revenue growth of 2.7% a year for 5 years; our model assumes 16.6% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of ₹1,965.20. A model estimate, not investment advice.
Lupin (LUPIN.NS) insider trading
We have no recent SEC Form 4 insider filings on file for Lupin Limited (LUPIN.NS). Form 4 covers US-listed companies only.
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.